The evidence makes the difference
Developing innovative cancer therapies
Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs.
Oncoethix’s product pipeline includes three first-in-class agents to novel cancer targets or with novel mode of action.
Two of these agents are in clinical development.
Presentations at the American Society of Hematology Annual Meeting
OncoEthix Closes 18 Million CHF (~US$19 Million) Series B Financing